Matthew Barcus
Stock Analyst at Chardan Capital
(2.88)
# 1,214
Out of 4,479 analysts
22
Total ratings
21.74%
Success rate
18.52%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Buy | $45 → $27 | $4.01 | +573.32% | 4 | Jun 22, 2023 | |
| ZURA Zura Bio | Initiates: Buy | $14 | $3.43 | +308.16% | 1 | Jun 14, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.89 | +686.52% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $26.52 | +20.66% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $11 | $0.37 | +2,875.39% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.27 | +296.48% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $11.70 | -31.62% | 1 | Mar 17, 2023 | |
| VINC Vincerx Pharma | Maintains: Buy | $4 → $3 | $0.74 | +307.06% | 3 | Nov 17, 2022 |
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $4.01
Upside: +573.32%
Zura Bio
Jun 14, 2023
Initiates: Buy
Price Target: $14
Current: $3.43
Upside: +308.16%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.89
Upside: +686.52%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $26.52
Upside: +20.66%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $11
Current: $0.37
Upside: +2,875.39%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.27
Upside: +296.48%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $11.70
Upside: -31.62%
Vincerx Pharma
Nov 17, 2022
Maintains: Buy
Price Target: $4 → $3
Current: $0.74
Upside: +307.06%